These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19912188)

  • 1. Patient-reported reasons for discontinuing overactive bladder medication.
    Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
    BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of discontinuing overactive bladder medications.
    Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
    BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
    Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
    BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges for managing overactive bladder and guidance for patient support.
    Schabert VF; Bavendam T; Goldberg EL; Trocio JN; Brubaker L
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S118-22. PubMed ID: 19355801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication nonadherence secondary to drug-induced memory loss.
    Nye AM; Clinard VB; Barnes CL
    Consult Pharm; 2010 Feb; 25(2):117-21. PubMed ID: 20211824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial.
    Lee YS; Choo MS; Lee JY; Oh SJ; Lee KS
    Int J Clin Pract; 2011 Sep; 65(9):997-1004. PubMed ID: 21849011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of overactive bladder on women in the United States: results of a national survey.
    Dmochowski RR; Newman DK
    Curr Med Res Opin; 2007 Jan; 23(1):65-76. PubMed ID: 17257467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bother related to bladder control and health care seeking behavior in adults in the United States.
    Benner JS; Becker R; Fanning K; Jumadilova Z; Bavendam T; Brubaker L;
    J Urol; 2009 Jun; 181(6):2591-8. PubMed ID: 19375096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
    Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
    Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
    Kay GG; Granville LJ
    Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
    Liu HT; Chancellor MB; Kuo HC
    BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients.
    Michel MC; Oelke M; Goepel M; Beck E; Burkart M
    Neurourol Urodyn; 2007; 26(2):190-5. PubMed ID: 17096320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.